Inicio/VRTX

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze VRTX in workspace
VRTXNASDAQ/health care

Vertex Pharmaceuticals Incorporated

$480.25Down-5.14 (-1.06%)
Research reviewed: 12 jul 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Vertex Pharmaceuticals Incorporated operates in Biotechnology within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

开盘
482.60
最高
484.32
最低
474.71
市值
1218.9亿
市盈率
28.52
52 周高点
--
股息
--
季度分红金额
--

3-month price context

El gráfico muestra la tendencia reciente de 3 meses para entender la estructura de corto plazo antes de abrir el workspace completo.

Investment thesis

Base case
ALYFTREK and expanded eligible populations can sustain the core franchise and reach additional patients. The base case remains conditional on franchise concentration staying manageable.
Bull case
ALYFTREK and expanded eligible populations can sustain the core franchise and reach additional patients. CASGEVY and JOURNAVX adoption can establish meaningful franchises beyond cystic fibrosis. Povetacicept regulatory and late-stage progress can create a fourth major disease-area franchise.
Bear case
Cystic fibrosis remains the main revenue source and is exposed to pricing, access and future competition. Gene-editing and pain products face complex patient identification, delivery and reimbursement pathways. Late-stage failures or regulatory delays could materially reduce pipeline diversification value.
Thesis invalidation
Reassess the thesis if cystic fibrosis remains the main revenue source and is exposed to pricing, access and future competition.

Key catalysts

  • Cystic-fibrosis leadership

    ALYFTREK and expanded eligible populations can sustain the core franchise and reach additional patients.

  • Commercial diversification

    CASGEVY and JOURNAVX adoption can establish meaningful franchises beyond cystic fibrosis.

  • Nephrology pipeline

    Povetacicept regulatory and late-stage progress can create a fourth major disease-area franchise.

Principal risks

  • Franchise concentration

    Cystic fibrosis remains the main revenue source and is exposed to pricing, access and future competition.

  • Launch execution

    Gene-editing and pain products face complex patient identification, delivery and reimbursement pathways.

  • Clinical-development risk

    Late-stage failures or regulatory delays could materially reduce pipeline diversification value.

Latest earnings research

Q1 2026

Vertex's first-quarter 2026 results reflected continued cystic-fibrosis leadership, growing contributions from CASGEVY and JOURNAVX and rapid advancement of the povetacicept-led nephrology pipeline while full-year guidance was reiterated.

Valuation interpretation

  • The core franchise supports cash generation, while premium growth depends on converting recent launches into durable non-CF revenue.
  • Pipeline optionality remains substantial but should be risk-adjusted for clinical outcomes, launch complexity and reimbursement.

Peer research

ABBVAMGNGILD

Recent news

Zacks · 4小时前

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

Motley Fool · 7小时前

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

Barchart · 12小时前

What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report

Simply Wall St. · 前天

Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada

MarketBeat · 前天

Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse

Motley Fool · 3天前

Is This Biotech Stock a Buy Near Its 52-Week High?

Data and research sources

Research updated: 12 jul 2026, 00:00 UTC
3 verified sources
Vertex Reports First Quarter 2026 Financial ResultsVertex Pharmaceuticals Incorporated · earningsVerified

Fetched: 12/7/2026, 0:00:00 UTC

Published: 4/5/2026, 0:00:00

Open original source
Vertex Pharmaceuticals Incorporated Investor RelationsVertex Pharmaceuticals Incorporated · companyVerified

Fetched: 12/7/2026, 0:00:00 UTC

Open original source
Vertex SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12/7/2026, 0:00:00 UTC

Published: 4/5/2026, 0:00:00

Open original source

Continue in the research workspace

Keep VRTX in context, run a multi-agent analysis, and monitor thesis changes.

Analyze VRTX free

Explora todo el sistema de análisis

Cada etapa cumple una función concreta y deja un resultado auditable.

Metodología de análisisLeer informes de mercadoExplorar acciones

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Analista Fundamental

Analista Fundamental se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Analista de Noticias

Analista de Noticias se especializa en la etapa de Observar dentro de Investigación central y ordena el contexto para los siguientes roles.

Gerente de Riesgo

Gerente de Riesgo se especializa en la etapa de Monitorizar dentro de Riesgo y monitoreo y ordena el contexto para los siguientes roles.